Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. [PDF]
, 2014 BackgroundCanine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma.
Burgess, KE +5 more
core +2 more sources
International Journal of Nephrology, 2018 Background. Hyperphosphatemia in chronic kidney disease (CKD) patients is often treated with calcium carbonate (CaCO3) despite the fact that CaCO3 is associated with increased calcium load and potentially increased cardiovascular risk.
B. L. Goh, A. Soraya, A. Goh, K. L. Ang
doaj +1 more source
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
Kidney International Reports, 2018 Serum phosphate levels are insufficiently controlled in many patients with end-stage renal disease (ESRD), and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodium-dependent phosphate co-transporter type 2b
Tobias E. Larsson +6 more
doaj +1 more source
Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis [PDF]
, 2015 AIMS: In Spain, the first line treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) consists of calciumbased phosphate binders (CB). However, their use is associated with vascular calcification and an increased mortality risk.
Antonio Galán +7 more
core +1 more source
Hypercalciuria in Postmenopausal Osteoporosis
Türk Osteoporoz Dergisi, 2004 Women aged between 35 to 75, termed as postmenopausal at least for one year, not smoking and not drinking alcohol, not using any medicine related with menopause and osteoporosis made up our patient and control groups.
Ayfer Kanberoğlu +3 more
doaj
Urinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease
Veterinary Sciences, 2017 The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD).
Cínthia Ribas Martorelli +6 more
doaj +1 more source
New Developments in Hyperphosphatemia Management [PDF]
Journal of the American Society of Nephrology, 2003 Patients with chronic renal failure have many associated medical problems, including a high propensity for cardiovascular disease (CVD). CVD and stroke are the leading causes of mortality in patients with ESRD (chronic kidney disease stage 5), with a 10- to 20-fold greater risk than in the general population (1,2).
openaire +2 more sources
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword [PDF]
, 2017 The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a selective update of the ...
Wheeler, DC, Winkelmayer, WC
core
Control of hyperphosphatemia beyond phosphate [PDF]
Kidney International, 2007 Hyperphosphatemia is a prevalent condition in the dialysis population and is associated with bad outcome. Block et al. present data from a post hoc analysis indicating that sevelamer, a noncalcium-containing phosphate binder, may confer a survival benefit in incident hyperphosphatemic hemodialysis patients.
openaire +2 more sources
Relationship of Conjunctival and Corneal Calcification with Secondary Hyperparathyroidism in Hemodialysis Patients [PDF]
, 2003 Background/Objective: Hyperphosphatemia is the consequence of end stage renal failure. Inadequate control of serum phosphorus results in elevated Ca×P product with subsequent soft tissue deposition in the form of conjunctival and corneal calcification ...
Baradaran, A. +3 more
core